Together, these findings suggest that therapeutic interventions that target the immunoproteasome/NF‐κB/NLRP3 inflammasome pathway may provide new opportunities for the future treatment of ischaemic stroke. This evidence concerns the gene NLRP3 and ischemic stroke.